Basic Financial Statements and Management's Discussion and Analysis

December 31, 2023



Independent Auditors' Report

The Board of Trustees Bermuda Institute of Ocean Sciences (BIOS), Inc.

Report on the Audit of the Financial Statements

Opinions

We have audited the accompanying financial statements of the business-type activities of Bermuda Institute of Ocean Sciences (BIOS), Inc. (a nonprofit organization), a blended component unit of Arizona State University, as of and for the year ended December 31, 2023, and the related notes to the financial statements, which collectively comprise Bermuda Institute of Ocean Sciences (BIOS), Inc.'s basic financial statements as listed in the table of contents.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the business-type activities of Bermuda Institute of Ocean Sciences (BIOS), Inc. as of December 31, 2023, and the changes in financial position and, where applicable, cash flows thereof for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinions

We conducted our audit in accordance with auditing standards generally accepted in the United States of America ("GAAS") and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of BIOS, and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about BIOS's ability to continue as a going concern for twelve months beyond the financial statement date, including any currently known information that may raise substantial doubt shortly thereafter.

The Board of Trustees Bermuda Institute of Ocean Sciences (BIOS), Inc. Page 2

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinions. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and Government Auditing Standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of BIOS's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about BIOS's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

The Board of Trustees Bermuda Institute of Ocean Sciences (BIOS), Inc. Page 3

Other Matters

Supplementary Information

Accounting principles generally accepted in the United States of America require that the management's discussion and analysis be presented to supplement the basic financial statements. Such information is the responsibility of management and, although not a part of the basic financial statements, is required by the Governmental Accounting Standards Board, who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic, or historical context. We have applied certain limited procedures to the required supplementary information in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audit of the basic financial statements. We do not express an opinion or provide any assurance on the information because the limited procedures do not provide us with sufficient evidence to express an opinion or provide any assurance.

PKF O'Connor Davies LLP

June 7, 2024

Management's Discussion and Analysis (Unaudited) December 31, 2023

Introduction Overview of the Financial Statements and Financial Analysis

This section of the Bermuda Institute of Ocean Sciences (BIOS) Inc. annual financial report presents management's discussion and analysis of the financial performance of BIOS for the fiscal year December 31, 2023. The discussion and analysis has been prepared by management and should be read in conjunction with the accompanying financial statements and footnotes.

Reporting Entity

Bermuda Institute of Ocean Sciences (BIOS), Inc., is a US nonprofit marine science research and education institute located in St. George's, Bermuda. BIOS research programs investigate the role of the ocean in global climate, health of coral reefs and international collaborative efforts beyond Bermuda waters. Bermuda's unique location allows researchers to access deep ocean, furthering our understanding of the biological, chemical and physical processes that underpin the ocean's role in regulating the Earth's climate. BIOS owns and operates the R/V Atlantic Explorer which is equipped with navigation, laboratory, technical systems and equipment that is instrumental in servicing sponsored research.

Education is a key aspect of BIOS's mission, directly linking our scientific research to hands-on learning opportunities for international and local students. BIOS offers education programs from the grade school level to university and internship opportunities. Educator workshops and visiting groups also complement our educational offerings.

In 2021 BIOS became a blended component unit of Arizona State University (ASU) and a unit of the Julie Ann Wrigley Global Futures Lab at ASU and the School of Ocean Futures.

Introduction to the Financial Statements

BIOS's financial statements include the following:

Statement of Net Position:

This Statement of Net Position is presented with three major categories: assets, liabilities and net position. The assets are classified between current and noncurrent. The current assets include cash and cash equivalents, short term investments, grants and accounts receivable, contributions receivable, inventory and prepaid expenses. The noncurrent assets include capital assets, long-term investments and net receivables due in excess of a year. Assets, liabilities and net position are reported on an accrual basis of accounting as of December 31, 2023.

Liabilities are also classified between current and noncurrent. Current liabilities include accounts payable and accrued expenses, loans payable within one year and unearned revenues. Noncurrent liabilities include long term debt payable after one year.

Net position consists of net investment in capital assets, restricted expendable and nonexpendable and unrestricted net position.

Statement of Revenues, Expenses and Changes in Net Position: The Statement of Revenues, Expenses, and Changes in Net Position presents the revenues earned and expenses incurred during the year on an accrual basis.

Management's Discussion and Analysis (Unaudited) December 31, 2023

Financial Overview

Net Position: Net position may serve over time as a useful indicator of an entity's financial position. The following table reflects the condensed Statement of Net Position of BIOS for December 31, 2023 and 2022 showing assets exceeded liabilities by \$40.5M at December 31, 2023.

	2023	2022	Increase / (Decrease)
ASSETS			
Current Assets	\$ 6,792,060	\$ 7,350,392	\$ (558,332)
Noncurrent Assets	21,946,350	18,643,129	3,303,221
Capital Assets, Net	13,873,914	15,031,504	(1,157,590)
Total Assets	42,612,324	41,025,025	1,587,299
LIABILITIES			
Current Liabilities	1,417,630	1,627,313	(209,683)
Noncurrent long term obligations	740,305	807,287	(66,982)
Total Liabilities	2,157,935	2,434,600	(276,665)
NET POSITION			
Net Investment in Capital Assets	13,066,626	14,162,060	(1,095,434)
Restricted:			
Nonexpendable	10,222,241	10,194,641	27,600
Expendable	13,607,011	14,481,920	(874,909)
Unrestricted	3,558,511	(248,196)	3,806,707
Total Net Position	\$40,454,389	\$38,590,425	<u>\$ 1,863,964</u>

Condensed Summary of Net Position December 31, 2023 and 2022

Assets: Total assets increased by \$1.6M during the year ended December 31, 2023. Current assets decreased \$0.5M between years while noncurrent assets increased by nearly \$2.1M. Lower current receivables and larger investment balances due to investment performance attribute to the current and noncurrent asset changes respectively.

Liabilities: Current liabilities decreased by nearly \$0.3M as payables declined. Noncurrent liabilities decreased by \$0.1M due to principal repayment on the sole remaining debt instrument related to a small capital improvement project as financed with a major local utility company.

Net Position: The \$1.9M increase in net position is due to positive investment returns and reduced operating expenditures.

Change in Net Position: The following table compares the revenues and expenses for the current and previous year.

Management's Discussion and Analysis (Unaudited) December 31, 2023

Condensed Summary of Revenues, Expenses and Changes in Net Position Years Ended December 31, 2023 and 2022

			Increase /
	2023	2022	(Decrease)
OPERATING REVENUE		A 44 470 570	• (4, 400, 050)
Research grants and contracts	\$ 10,308,528	\$ 11,470,578	\$ (1,162,050)
Tuition and fees	1,049,871	457,024	592,847
Auxiliary enterprises	575,861	490,828	85,033
Total Operating Revenue	11,934,260	12,418,430	(484,170)
OPERATING EXPENSES			
Instruction	1,742,890	976,162	766,728
Research	9,423,424	10,594,041	(1,170,617)
Institutional support	2,322,043	2,755,077	(433,034)
Operation and maintenance of plant	849,424	753,913	95,511
Auxiliary enterprises	265,964	176,461	89,503
Academic support	404,687	403,393	1,294
Depreciation	1,979,039	2,079,731	(100,692)
Total Operating Expenses	16,987,471	17,738,778	(751,307)
Operating Loss	(5,053,211)	(5,320,348)	267,137
NONOPERATING REVENUES (EXPENSES)			
Private gifts	2,240,556	2,541,071	(300,515)
Investment return (loss)	1,068,234	(2,979,180)	4,047,414
Other revenues (loss)	2,000	(1,003)	3,003
Affiliation services revenue	3,711,347	4,381,514	(670,167)
Interest on debt	(63,101)	(279,381)	216,280
Loss on disposals	(41,861)		(41,861)
Net Nonoperating Revenues	6,917,175	3,663,021	3,254,154
Change in Net Position	1,863,964	(1,657,327)	3,521,291
NET POSITION			
Beginning of year	38,590,425	40,247,752	(1,657,327)
End of year	\$40,454,389	\$ 38,590,425	<u>\$ 1,863,964</u>

Revenues: Total operating revenue decreased by \$0.5M over prior year. Lower research revenues from decreased vessel operating costs were offset by increases in tuition and auxiliary revenues as visitor group related educational activities returned to pre-pandemic levels.

Management's Discussion and Analysis (Unaudited) December 31, 2023

Expenses: Total operating expenses decreased by \$0.8M over prior year. Research expenditures decreased by \$1.1M while instructional expenditures increased by about \$0.8M. In 2023, there was no bi-annual shipyard for the R/V Atlantic Explorer which historically incurred costs upwards of \$1.0M for those periods.

Nonoperating expenses and revenues: Total nonoperating activity increased by \$3.2M. Unrealized gains on investments of nearly \$1.0M were partially offset with slight decreases in other nonoperating activity. In 2022, BIOS recorded significant losses on investments.

Statement of Net Position December 31, 2023

ASSETS

Current Assets	
Cash and cash equivalents	\$ 3,068,349
Grants and accounts receivable	1,418,657
Contributions receivable	2,236,101
Inventory and prepaid expenses	68,953
Total Current Assets	6,792,060
Noncurrent Assets:	
Investments	21,946,350
Capital assets, net	13,873,914
Total Noncurrent Assets	35,820,264
Total Assets	<u>\$ 42,612,324</u>
LIABILITIES AND NET POSITION	
Liabilities	
Current Liabilities	
Accounts payable and accrued expenses	\$ 683,758
Unearned revenue	666,889
Loans payable	66,983
Total Current Liabilities	1,417,630
Noncurrent Liabilities	
Loans payable	740,305
Total Liabilities	2,157,935
Net Position	
Net investment in capital assets	13,066,626
Restricted	
Nonexpendable	10,222,241
Expendable	13,607,011
Unrestricted	3,558,511
Total Net Position	40,454,389
Total Liabilities and Net Position	<u>\$ 42,612,324</u>

Statement of Revenues, Expenses and Changes in Net Position Year Ended December 31, 2023

OPERATING REVENUE Research grants and contracts	\$ 10,308,528
Tuition and fees	1,049,871
Auxiliary enterprises	575,861
Total Operating Revenue	11,934,260
	,
OPERATING EXPENSES	
Instruction	1,742,890
Research	9,423,424
Institutional support	2,322,043
Operation and maintenance of plant Auxiliary enterprises	849,424 265,964
Academic support	404,687
Depreciation	1,979,039
•	16,987,471
Total Operating Expenses	10,007,471
Operating Loss	(5,053,211)
NONOPERATING REVENUES (EXPENSES)	
Contributions	2,240,556
Investment return	1,068,234
Other revenue	2,000
Affiliation services revenue	3,711,347
Interest on debt	(63,101)
Loss on disposals	(41,861)
Net Nonoperating Revenues	6,917,175
Change in Net Position	1,863,964
NET POSITION	
Beginning of year	38,590,425
End of year	<u>\$ 40,454,389</u>

See notes to financial statements

Statement of Cash Flows Year Ended December 31, 2023

CASH FLOWS FROM OPERATING ACTIVITIES	
Tuition and fees	\$ 1,085,876
Research grants and contracts	12,853,360
Sales and services of auxiliary enterprises	666,845
Payments of employees for salaries and benefits	(7,790,775)
Payments to suppliers	(7,483,155)
Net Cash from Operating Activities	(667,849)
CASH FLOWS FROM NON CAPITAL FINANCING ACTIVITIES	
Affiliation services revenue	3,711,347
Contributions	2,240,556
Net Cash from Noncapital Financing Activities	5,951,903
CASH FLOWS FROM CAPITAL AND RELATED FINANCING ACTIVITIES	
Proceeds from sale of capital assets	2,000
Purchases of capital assets	(863,311)
Principal paid on capital debt	(62,157)
Interest paid on capital debt	(63,101)
Net Cash from Capital and Related Financing Activities	(986,569)
CASH FLOWS FROM INVESTING ACTIVITIES	
Purchase of ASU Foundation long term investment pool	(14,064,701)
Purchases of investments	(5,107,310)
Proceeds from sales of investments	742,704
Net Cash from Investing Activities	(18,429,307)
Net Decrease in Cash and Cash Equivalents	(14,131,822)
CASH EQUIVALENTS AND ENDOWMENT CASH	
Beginning of year	17,200,171
End of year	<u>\$ 3,068,349</u>
RECONCILIATION OF OPERATING LOSS TO	
NET CASH FROM OPERATING ACTIVITIES	
Operating loss	\$ (5,053,211)
Adjustments to reconcile net loss to net cash from operating activities	Ψ (0,000,211)
Depreciation expense	1,979,039
	1,979,039
Changes in assets and liabilities Grants and accounts receivable	210 720
	310,738
Contributions receivable	2,273,178
Inventory and prepaid expenses	36,915
Accounts payable and accrued expenses	(303,139)
Unearned revenues	88,631
Net Cash from Operating Activities	<u>\$ (667,849</u>)

See notes to financial statements

Notes to Financial Statements December 31, 2023

1. Organization

Bermuda Institute of Ocean Sciences (BIOS), Inc., formerly The Bermuda Biological Station for Research, Inc., founded in 1903, was incorporated in the State of New York in 1926 as a U.S. not-for-profit research organization. BIOS is exempt from U.S. income taxes pursuant to Sections 501(c)(3) and 509(a) of the Internal Revenue Code. BIOS is also a Bermuda Registered Charity (Reg #116).

On October 26, 2021, BIOS and Arizona State University ("ASU"), a related party, executed a services and affiliation agreement. Based on the terms of the agreement and in accordance with Government Accounting Standards Board (GASB) Statement No. 80, BIOS is considered a blended component unit of Arizona State University for financial reporting purposes. Accordingly, the financial statements of BIOS are included in Arizona State University's Annual Comprehensive Financial Report.

BIOS's mission is to seek and share fundamental knowledge of the oceans through stateof-the-art scientific research, world-class field expeditions, and comprehensive educational experiences.

The research conducted at BIOS is relevant to the waters surrounding Bermuda, as well as the global Earth system, and is multidisciplinary, spanning the biological, chemical, geological, and physical sciences. BIOS researchers are active partners in regional and international research collaborations that are working to address some of the most pressing issues of our time including climate change, marine conservation, ecosystem health, and natural-disaster risk assessment.

2. Summary of Significant Accounting Policies

Basis of Presentation

The financial statements of BIOS are presented under the economic resources measurement focus and prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (US GAAP) applicable to government entities, established primarily by the Governmental Accounting Standards Board (GASB).

GASB establishes standards for external financial reporting and requires that resources be classified for accounting and reporting purposes into the following net position categories.

- Net investment in capital assets: Capital assets, net of accumulated depreciation, and outstanding principal balances of debt attributable to the acquisition, construction, or improvement of those assets.
- Restricted:

Nonexpendable – Net position subject to externally imposed stipulations that must be maintained permanently by BIOS.

Expendable – Net position whose use by BIOS is subject to externally imposed stipulations that can be fulfilled by actions of BIOS pursuant to the stipulations or that expire by the passage of time.

Notes to Financial Statements December 31, 2023

2. Summary of Significant Accounting Policies (continued)

Basis of Presentation (continued)

• Unrestricted:

Net position not subject to externally imposed stipulations that may be designated for specific purposes by action of management or the Board of Trustees, or may otherwise be limited by contractual agreements with outside parties.

When an expense is incurred that can be paid using either restricted or unrestricted resources, BIOS's policy is to first apply the expense towards restricted resources, and then towards unrestricted resources.

Use of Estimates

The presentation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Contributions

Contributions, including unconditional promises to give, are recognized as revenue in the period received or pledged. BIOS reports gifts as restricted support if they are received with donor stipulations that limit the use of the donated assets, or if they are restricted as support for future periods. When donor restrictions expire, that is, when a stipulated time restriction ends or purpose restriction is accomplished, expendable restricted net position is reclassified to unrestricted net position. Contributions of assets other than cash are recorded at their estimated fair value and are recorded as an increase in unrestricted net position unless the donor places restrictions on their use. Contributions due after one year are reported at their net present value. Amortization of the discount is recorded annually as additional contribution revenue over the anticipated collection period of the pledge.

Operating Expenses

Expenses are categorized as operating or nonoperating per GASB. BIOS reports operating expenses by functional category (instruction, research, etc.) in the statement of revenues, expenses, and changes in net position and displays expenses by their natural classification (personal services and benefits, supplies and services and depreciation).

Foreign Currency

BIOS's reporting currency is United States dollars ("USD") and the functional currency is Bermuda dollars ("BMD"). There are no foreign currency transaction gains or losses from transacting in BMD because the transactions denominated in BMD are translated to USD at par as the BMD is pegged to the USD at the exchange rate of one BMD to one USD.

Notes to Financial Statements December 31, 2023

2. Summary of Significant Accounting Policies (continued)

Cash Equivalents

All highly liquid investments, with maturities of three months or less at the time of purchase are considered cash equivalents.

Allowance for Uncollectible Receivables

An allowance for uncollectible receivables is estimated based on a combination of writeoff history, aging analysis and any specific known troubled accounts. Management believes all receivables are fully collectible, therefore, no allowance for doubtful accounts is recognized at year-end.

Inventory

Inventory is reported at the lower of cost or net realizable value (first in, first out) and consists of glider batteries, gift shop merchandise, cafeteria, laboratory and SCUBA supplies held for resale. Glider batteries are unit stores expensed at the time of deployment in glider missions.

Fair Value Measurements

BIOS follows the provisions of GASB Statement No. 72, *"Fair Value Measurement and Application"*, which defines fair value and establishes a fair value hierarchy organized into three levels based upon the input assumptions used in pricing assets. Level 1 inputs have the highest reliability and are related to assets with unadjusted quoted prices in active markets. Level 2 inputs relate to assets with other than quoted prices in active markets which may include quoted prices for similar assets or liabilities or other inputs which can be corroborated by observable market data. Level 3 inputs are unobservable inputs and are used to the extent that observable inputs do not exist.

The fair values of nonmarketable securities are based on valuations provided by external investment managers.

Investment Valuation and Income Recognition

Investments are carried at fair value. Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis and dividends are recorded on the ex-dividend date. Realized and unrealized gains and losses are included in the determination of the change in net position.

Risk Disclosure

Interest Rate Risk - Interest rate risk is the risk that BIOS will incur losses in fair value caused by changing interest rates. BIOS has a formal investment policy that considers investment maturities as a means of managing its exposure to fair value losses arising from changing interest rates.

Custodial Credit Risk - Custodial credit risk is the risk that in the event of a bank failure, BIOS's deposits may not be returned to it. GASB Statement No. 40, "*Deposit and Investment Risk Disclosures – an amendment of GASB Statement No. 3*", directs that deposits be disclosed as exposed to custodial credit risk if they are not covered by

Notes to Financial Statements December 31, 2023

2. Summary of Significant Accounting Policies (continued)

Risk Disclosure (continued)

depository insurance and the deposits are either uncollateralized, collateralized by securities held by the pledging financial institution or collateralized by securities held by the pledging financial institution's trust department but not in BIOS's name. Deposits held at financial institutions insured by the Federal Deposit Insurance Corporation ("FDIC") are insured up to \$250,000. BMD dollar deposits by charities held at financial institutions insured by the Bermuda Deposit Insurance Corporation ("BDIC") are insured up to \$25,000. Investment holdings at financial institutions insured by the Securities Investor Protection Corporation ("SIPC") are insured up to \$500,000 (\$250,000 for cash holdings). As of December 31, 2023, BIOS's uninsured cash and cash equivalents balances on deposit totaled approximately \$2,758,000. As of December 31, 2023, BIOS's uninsured investment holdings totaled approximately \$20,946,000. BIOS does not have a deposit policy for custodial credit risk, but has not experienced any losses in such accounts, and management believes it is not exposed to any significant risks related to these accounts.

Credit Risk - Credit risk is the risk that an issuer or other counterparty will not fulfill its specific obligation even without the entity's complete failure. BIOS does not have a formal credit risk policy.

Research Grants and Contracts Revenue Recognition

Grants to BIOS are either reimbursement of costs limited by the maximums stated in the grant or are fixed price contracts. Support under grants for reimbursement of costs is recognized in the same period and in an amount equivalent to the aggregate of the incurred underlying costs. Revenue from fixed price grants is recognized proportionately over the life of the grant, as defined in the contract.

Tuition and fees

Tuition and fees are recognized over the period the tuition and other services are provided. Prepayments are recorded as unearned revenue.

Capital Assets

Purchases of capital assets are recorded at cost. Gifts or contributions of capital assets are recognized at fair value at the time received. Capital assets are depreciated using the straight-line method over the estimated useful lives of the assets. When items are disposed, the cost and accumulated depreciation are eliminated from the records of account, and a gain or loss is reported in current income. Repair and maintenance charges that do not increase the lives of the assets are expensed as incurred.

Capital Assets of BIOS are depreciated over the following useful lives:

	Useful Lives
Buildings and improvements	20-40 years
Furniture, fixtures and equipment	5-15 years
R/V Atlantic Explorer	25 years

1 I. . **.** . I I

Notes to Financial Statements December 31, 2023

2. Summary of Significant Accounting Policies (continued)

Asset Recoverability

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying value amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized in the amount by which of the carrying amount of the asset exceeds the fair value of the asset. Management has concluded that an impairment charge for 2023 is not necessary.

Accounting for Uncertainty in Income Taxes

BIOS recognizes the effect of income tax positions only when they are more likely than not to be sustained. Management has determined that BIOS had no uncertain income tax positions that require financial statement recognition or disclosure. BIOS is no longer subject to examination by the applicable taxing jurisdictions for periods prior to 2020.

Subsequent Events

Management has evaluated subsequent events for disclosure and/or recognition in the financial statements through June 7, 2024, the date financial statements were available for issuance.

3. Concentrations of Financial Risk

Financial instruments that potentially subject BIOS to concentrations of credit and market risk consist principally of cash, cash equivalents, and endowment cash on deposits with financial institutions, investments held at financial institutions, and receivables.

The investment portfolio is diversified by type of investment and industry concentrations so that no individual investment, investment advisor, investment manager or group of investments represents a significant concentration risk.

At December 31, 2023 grants and accounts receivable from one grantor totaled approximately \$691,000. At December 31, 2023, gross contributions receivable due from one donor totaled approximately \$2,236,000.

For the year ended December 31, 2023 research grants and contracts from one grantor totaled approximately 82% of research grants and contracts. For the year ended December 31, 2023 contributions from one donor totaled approximately 22% of contributions.

Notes to Financial Statements December 31, 2023

4. Related Party Transactions

For the year ended December 31, 2023, as part of ASU and BIOS's services and affiliation agreement, ASU paid BIOS for the following activities:

ASU affiliation and service agreement	\$ 2,800,000
Deferred maintenance	225,000
ASU BIOS faculty support	 686,347
	\$ 3,711,347

5. Contributions Receivable

Contributions receivable at December 31, 2023 expected to be collected in one year or less totaled \$2,236,101.

6. Investments

In December 2022, BIOS and Arizona State University Foundation ("ASUF"), a private nonprofit organization that engages private supporters to advance the success for ASU as a New American University, executed an Investment Services Agreement ("ISA") for ASUF to succeed as Investment Administrator for the BIOS Endowment. In December 2023, BIOS liquidated their endowment assets to transfer and invest in the ASUF Long Term Investment Pool (the "Pool").

BIOS endowment assets are invested in ASUF's endowment Pool and performance is allocated proportionally to its share of the Pool activity. ASUF's responsibility is to hold, manage, invest and make distributions from the fund with oversight to establishing investment policies and management of the Pool. As such, the ASUF owns the Pool assets and BIOS has an interest in the Pool which is considered an external investment asset to BIOS. The Pool invests in a variety of asset classes including common stocks, fixed-income, foreign investments, private equity and hedge funds. The ASUF Endowment Pool is not registered with the Securities and Exchange Commission as an investment company.

ASUF Board of Directors-appointed Investment Committee includes members of the ASUF Board of Directors. The fair value of BIOS's position in the Pool is based on BIOS's proportionate share of the Pool which is marked-to-market monthly.

The following presents investments recorded at fair value at December 31, 2023 and are measured as follows:

Treasury Money Market Fund	\$ 7,692,276
ASUF Long Term Investment Pool *	14,254,074
Total Investments	\$21,946,350

At December 31, 2023, the Treasury Money Market Fund has a fair value measurement of level 2 inputs.

* As noted above, these funds relate to BIOS's endowment and are managed by ASUF. While these funds are reported at fair value using the practical expedient, they are not classified within the fair value hierarchy.

Notes to Financial Statements December 31, 2023

7. Capital Assets

Capital assets activity for the year ended December 31, 2023 is comprised of the following:

	Beginning Balance Additions		Reductions	Ending Balance
Non-depreciated capital assets				
Land and land improvements	\$ 486,850	\$-	\$-	\$ 486,850
Depreciable Capital Assets				
Buildings and improvements	16,630,006	91,242	-	16,721,248
Furniture, fixtures & equipment	7,449,790	665,066	(330,641)	7,784,215
R/V Atlantic Explorer	15,232,846	107,003	(99,804)	15,240,045
	39,312,642	863,311	(430,445)	39,745,508
Total Capital Assets	39,799,492	863,311	(430,445)	40,232,358
Accumulated depreciation				
Buildings and improvements	9,648,728	404,025	-	10,052,753
Furniture, fixtures & equipment	5,169,975	541,607	(293,959)	5,417,623
R/V Atlantic Explorer	9,949,286	1,033,407	(94,625)	10,888,068
Total Accumulated Depreciation	24,767,989	1,979,039	(388,584)	26,358,444
Capital assets, net	<u>\$15,031,503</u>	<u>\$ (1,115,728)</u>	<u>\$ (41,861</u>)	<u>\$ 13,873,914</u>

8. Loans Payable

Loans payable consist of the following at December 31, 2023:

Loan payable (unsecured) to Air Care Limited pursuant to the Energy Performance Contract, payable in monthly installments of \$10,438, including interest at 7.5%, due March, 2032.

\$ 807,288

Aggregate maturities of loans payable approximate \$67,000 in 2024, \$72,000 in 2025, \$78,000 in 2026, \$84,000 in 2027, \$90,000 in 2028 and \$416,000 thereafter. Interest expense totaled approximately \$63,000 for year ended December 31, 2023.

9. Sponsored Projects

Approximately 54% of revenues in 2023 are awards for sponsored projects (governments and other sources). The awards generally provide for recovery of both direct and indirect costs. The indirect costs covered by the awards are determined as a negotiated or agreed-upon percentage of direct costs with certain exclusions.

Notes to Financial Statements December 31, 2023

10. Operating Expenses by Natural Classification

Operating expenses by functional and natural classification for the year ended December 31, 2023, are summarized as follows:

	Personal Services and Benefits	Supplies and Services	Depreciation	Total
Instruction	\$ 676,974	\$ 1,065,916	\$-	\$ 1,742,890
Research	3,933,943	5,489,481	-	9,423,424
Academic support	370,294	34,393	-	404,687
Institutional support	1,905,933	416,110	-	2,322,043
Operation and maintenance of plant	334,348	515,076	-	849,424
Auxiliary enterprises	569,018	(303,054)	-	265,964
Depreciation			1,979,039	1,979,039
Total Operating Expenses	\$7,790,510	\$7,217,922	\$1,979,039	\$ 16,987,471

11. Pension Plan

BIOS maintains a contributory pension plan for employees ages 23 and over who have worked at least 720 hours in any calendar year. Participation in the plan is mandatory for Bermudians and spouses of Bermudians until they are 65 years old. The plan is voluntary for all other employees. Each participating employee may contribute to the plan up to a maximum of 10% of their gross salary. Mandatory participants must contribute 5%. BIOS matches the employee contribution of 5% of gross salary in accordance with the plan documents and the Bermuda Occupational Pensions Act 1998. Pension expense for the year ended December 31, 2023 approximated \$265,000.

12. Endowment Funds

Donor-restricted funds whose purpose is to provide long-term support for BIOS and its charitable programs are endowment funds. Net position of endowment funds are classified as restricted or unrestricted as determined by the directions of donors, where applicable, and the provisions of the laws of the State of New York. Absent donor stipulations to the contrary, the provisions of New York State law do not impose restrictions on the use of income or capital appreciation derived from the original gift.

BIOS adheres to the New York State Uniform Prudent Management of Institutional Funds Act (NYPMIFA). NYPMIFA includes provisions that differ from previous law, including the elimination of the historic dollar value rule with respect to endowment spending, establishment of new standards governing the expenditure and modification of restrictions on endowment funds, and revision of the prudence standard for the management and investment of endowment funds.

Interpretation of Law

BIOS interprets NYPMIFA as requiring the preservation of the fair value of the original gift as of the date of the gift absent explicit donor stipulations to the contrary. As a result of this interpretation, BIOS classifies as nonexpendable restricted (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts

Notes to Financial Statements December 31, 2023

12. Endowment Funds (continued)

donated to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the nonexpendable restricted endowment fund that is not classified in nonexpendable restricted is classified as expendable restricted until those amounts are appropriated for expenditure.

Investment Philosophy

The Fund has a long-term investment horizon and the trustees believe that asset allocation is the major determinant of investment performance. The asset allocation plan is based on a number of factors, including – projected spending needs, maintenance of sufficient liquidity to meet spending payments, and return objectives and risk tolerances. The asset allocation plan provides for diversification of assets to maximize the investment return and manage the endowment investments consistent with market conditions. Investments are made through recognized third-party providers of multimanager strategies.

Investment Return Objectives

BIOS has adopted investment and spending policies for the BIOS endowment fund (the Fund) with the core objective to provide a reliable source of long-term financial support. It is the desire of the trustees that the Fund achieves a balance of growth and stability and thereby, over the long term, earns a competitive rate available in the capital markets at the risk level prescribed for the Fund.

Spending Policy

It is BIOS policy to annually distribute up to 5% of a three-year moving average of the Fund's market value as of June 30 of each year. In 2023, the full 5% was eligible for distribution to support the operations of BIOS.

Cumulative investment returns in excess of the spending rate that are not donor-restricted are board designated endowment funds. Restricted endowment earnings represent cumulative investment returns which must be spent in accordance with the donors' intent. Permanently restricted endowments must be maintained in perpetuity.

Activity Summary

The following summarizes activity in endowment funds for year ended December 31, 2023:

	Unrestricted	Expendable Restricted	Nonexpendable Restricted	Total
Balance at January 1, 2023 Contributions	\$1,293,406 -	\$2,602,155 -	\$ 10,194,641 27,600	\$ 14,090,202 27,600
Investment management fees	(3)	(273)	-	(276)
Capital appreciation	160,526	737,429	-	897,955
Appropriated for expenditure	(136,541)	(624,866)		(761,407)
Balance at December 31, 2023	\$1,317,388	\$2,714,445	\$ 10,222,241	\$ 14,254,074

Notes to Financial Statements December 31, 2023

13. Expendable Restricted Net Position

Expendable restrictions are available for the purposes listed below as of December 31, 2023:

Scientific research	\$ 10,636,311
Education	2,348,356
Laboratory building	170,876
Future periods and administrative	451,468
	\$ 13,607,011

Investment return from nonexpendable restrictions held and subject to BIOS spending policy and appropriation is available to support the indicated activities at December 31, 2023:

Scientific research	\$	5,185,793
Education		3,558,477
Laboratory building		350,000
General operations	_	1,127,971
	\$	10,222,241

Releases from expendable restricted net position consist of the following for the year ended December 31, 2023:

Scientific research	\$ 2,941,593
Education	845,846
Laboratory building	 91,464
	\$ 3,878,903

* * * * *